The Ontario Institute for Cancer Research and the Structural Genomics Consortium in Toronto developed a new drug prototype, called OICR-9429, and made it freely available to the research community.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe